Slide 1: Investor Presentation October 2024
(ASX:MEM) INVESTOR PRESENTATION OCTOBER 2024
Slide 2: Disclaimer
DISCLAIMER This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell Memphasys Limited securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on
Slide 3: Who is Memphasys
WHO IS MEMPHASYS 1. * 19 “i
Slide 4: Underpinned by Strong Fundamentals, Already Commercialised
ALREADY COMMERCIALISED UNDERPINNED BY STRONG FUNDAMENTALS A reproductive biotechnology company already Highly credentialled innovation team and an 1 1 experienced board, executing commercialisation selling its first commercial product strategy 2 Diverse and innovative pipeline focusing on Exceptiona
Slide 5: Our Leaders
OUR LEADERS Distinguished Emeritus Professor John Aitken Memphasys Scientific Director Global leader in reproductive biology, heading up world-class research team at University of Newcastle. Leads development of MEM’s pipeline products through R&D, proof-of-concept to commercial strategy stage
Slide 6: Leadership Team
LEADERSHIP TEAM Experienced at bringing products to market Robert Cook Dr. David Ali Paul Wright Michael Atkins Assoc. Prof Chairman CEO NE Director NE Director Hassan Bakos Director Operations 40 years’ experience in healthcare 35 years’ experience in Animal and More than 25 years’ experience
Slide 7: Felix System: Better Technology for IVF Sperm Preparation
2. FELIX SYSTEM: BETTER TECHNOLOGY FOR IVF SPERM PREPARATION
Slide 8: A Global Issue, Large Addressable Market
A GLOBAL ISSUE LARGE ADDRESSABLE MARKET Average total fertility rate Global fertility decreasing – males account Fertility rate (births per woman) for ~50% 1 in 6 couples experience fertility issues Sperm dysfunction is the single most common cause of infertility Little progress in sperm proce
Slide 9: Felix System: Better technology for IVF sperm preparation
FELIX SYSTEM: Better technology for IVF sperm preparation Electrophoretic system selects sperm with both low DNA damage & oxidative stress Device consists of a console which applies a controlled 9 charge to a disposable cartridge Console Cartridge contains the novel electrophoretic technology Cartri
Slide 10: Felix System: Advantages over traditional methods
FELIX SYSTEM: Advantages over traditional methods Conventional DGC (Density Gradient Centrifugation) and/or swim-up processes* VS Felix System Process: 30-60+ minutes Rapid - six minutes Multi-step & labour intensive Single vessel & automated Specialised clinical operators Easy to train and operate
Slide 11: Felix System: Commercialisation Strategy
FELIX SYSTEM: Commercialisation Strategy Global Opportunity - starts with early Initial focus is to build sales in four early access markets: access markets Country Fresh IVF Expected % growth KOL % of global Initial focus - rollout of commercial sales in early access Cycles in fresh IVF rate enga
Slide 12: Japan Early Access Market – expanding into Canada & New Zealand
FELIX SYSTEM: Japan Early Access Market – expanding into Canada & New Zealand Choosing the right partner – Vitrolife Japan KK (subsidiary of the Vitrolife Group) Exclusive distribution agreement signed for a 5-year term Vitrolife Group is a world-leading global provider of medical devices, consu
Slide 13: Japan Early Access Market
FELIX SYSTEM: Japan Early Access Market What has been achieved – future plans 2023 Initial sales May 2024, positive findings from Undertaking larger clinical trial to order from Japanese clinical trial published, conclusively demonstrate absolute benefits prestigious Kobe which found Felix Sys
Slide 14: India Early Access Market
FELIX SYSTEM: India Early Access Market What has been achieved – future plans Dec 2021: Initial sales March 2022: Follow-up Sept 2023: The study resulted in 11 live births, matching MEM seeking of the Felix System orders placed by the same Australia and NZ benchmarks, particularly notable fo
Slide 15: Felix - Strategic Equine Fertility Study
FELIX - STRATEGIC EQUINE FERTILITY STUDY TM Initial Results Highly Positive, Validate Commercial Potential Three-year study being conducted in conjunction with the Three-year equine fertility study to position Felix as a leading University of Newcastle and EquiBreedUK Ltd, a global technology for
Slide 16: Major Regulated Markets 2024-2025 – To Be Pursued With Strategic Partners
FELIX SYSTEM: TM Major Regulated Markets 2024-2025 – To Be Pursued With Strategic Partners* Recently published Pre- Regulator Clinical Trials Comments data on IVF cycle submission numbers Regulatory Strategy – CE mark Application pending post trial • MEM pursuing CE mark Clinical trial (currently 90
Slide 17: Recent M&A in This Space
RECENT M&A IN THIS SPACE CooperSurgical Vitrolife's Purchase of Hamilton Thorne's FUJIFILM Irvine Origio’s Merger with Acquisition of Zymot Igenomix Acquisition of IVFtech Scientific's Partnership Research Instruments (Feb 2023) (Aug 2022) (Jan 2023) (June 2023) (April 2022) CooperSurgical Vitro
Slide 18: Felix Publications
FELIX PUBLICATIONS TM Memphasys has completed a number of published clinical studies into the use of the Felix device in comparison with more traditional sperm separation techniques. Studies include: Earlier prototype: CS-10 C. Ainsworth, B. Nixon & R.J. Aitken Development of a novel electrophoretic
Slide 19: Felix Project Timelines
FELIX PROJECT TIMELINES TM 2024 2025 2026 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Oct Jan Apr Jul Oct Jan Apr Jul Oct Clinical Trials FelixTM System in collaboration with Monash Japan Felix Trial CE Mark Approval CE Mark Submission CE Mark Review CE Mark Approval TGA Approval TGA Submission TGA Review TGA Approv
Slide 20: Oxidative Stress Measurement System: A Rapid In Vitro Antioxidant Assessment
3. OXIDATIVE STRESS MEASUREMENT SYSTEM: A RAPID IN VITRO ANTIOXIDANT ASSESSMENT
Slide 21: The Issue: Oxidative & Reductive Stress – Serious chemical imbalances
THE ISSUE: Oxidative & Reductive Stress – Serious chemical imbalances Oxidative stress - an imbalance between reactive oxygen species and antioxidant protection within the body and can also severely affect fertility in both humans and animals. Reductive stress - an abnormal accumulation of reduc
Slide 22: Simple Explanation
SIMPLE EXPLANATION Oxidative stress is like rust forming on metal. Just as metal rusts when it's exposed to oxygen over time, your body can "rust" or get damaged inside when it has too many harmful molecules (free radicals) and not enough of the good ones (antioxidants) to protect it. For example, i
Slide 23: The Issue: The adverse effect of oxidative / reductive stress imbalance
THE ISSUE: The adverse effect of oxidative / reductive stress imbalance Oxidative stress Reductive stress MEMPHASYS OPERATES IN THE MIDDLE Aging Chronic inflammatory disease Memphasys is helping Heart failure Impaired sperm production and maturation Cancer to avoid both Neurogenesis inhi
Slide 24: What Has Memphasys Done – Doing Now?
WHAT HAS MEMPHASYS DONE – DOING NOW ? - Developed the Oxidative Stress Measurement System: Positive assay results, with distinct time advantages (6 minutes). Oxidative Stress is not routinely measured due to the slow and complex methods currently used - Run KOL studies, positive results achieved - B
Slide 25: Oxidative Stress Measurement System Schematic
OXIDATIVE STRESS MEASUREMENT SYSTEM SCHEMATIC Principle on which Design concept for the cartridge Design concept for initial work station – Oxidative Stress first step before developing fully Measurement System automated system works Exploded view Assemble Outer Case Enclosure onto the Chamber assem
Slide 26: Unmet Diagnostic Need: Technology can address multiple needs and large global market
UNMET DIAGNOSTIC NEED: Technology can address multiple needs and large global market Current Practice Oxidative Stress Measurement System Testing for oxidative stress is rare: Several advantages over Current Practice: Point of care diagnostic device Complex equipment Six-minute process Time-consumin
Slide 27: Commercial Applications
COMMERCIAL APPLICATIONS TARGET MARKET AND OPPORTUNITY Estimated User group Application Market Size1 Fertility researchers* Researching underlying etiology of infertility & gestational issues $3b IVF clinics Screening for infertility issues in male and female patients $3b Obstetricians Diagnosi
Slide 28: Oxidative Stress Measurement System
OXIDATIVE STRESS MEASUREMENT SYSTEM Important application in the reproductive animal industry (husbandry, meat quality) • Klean Gene Pty Ltd, established by animal Oxidative stress: sector executives Michael Cameron & Rod Important role in animal genetics and husbandry Wellstead, assisting evaluate
Slide 29: Update on Development
UPDATE ON DEVELOPMENT Study Design & Methodology 2–3-month study to establish a baseline and thresholds for oxidative stress likely to be associated with meaningful events in reproductive performance. Determination of these events when correlated with reproductive performance could provide signi
Slide 30: Other Animal Applications
4. OTHER ANIMAL APPLICATIONS
Slide 31: Other Applications – AI Port
OTHER APPLICATIONS – AI PORT Maintains the viability of livestock semen for up to Offers considerable efficiency and quality seven days at a temperature range of 22 – 25oC improvements over current practice Enables collection and transportation of semen without Estimated addressable beef (no
Slide 32: Financial Snapshot
5. FINANCIAL SNAPSHOT
Slide 33: Memphasys Financial Snapshot
MEMPHASYS FINANCIAL SNAPSHOT: As at 09/10/2024 KEY DATA1 A$ $2M capital raising to expedite commercialisation activities Share price $0.008 Shares on issue 1,367.7M A$1M strongly supported by existing shareholders and new sophisticated and professional investors Market capitalisation $10.9M Shar
Slide 34: Memphasys: Set for growth
MEMPHASYS: Set for growth NEW OPENING PIPELINE UNMET NEED TALENT MARKETS BUILDING CEO Clear pathways to Product R&D Prof John Aitken Director with market for each strategy (Scientific corporate advisory product exclusively Director) & experience Commitment addressing unmet University of
Slide 35: Thank you
Thank you CONTACT INFORMATION: Dr David Ali CEO and Executive Director Memphasys Limited 30-32 Richmond Rd, Homebush NSW 2140 Australia P +612 8415 7300 E david.ali@memphasys.com M + 61 428794909 W www.memphasys.com